Mepivacaïne Hcl B. Braun (Mepivacaine Hydrochloride)

Mepivacaine blocks voltage‑gated sodium channels on nerve membranes, stabilising them in an inactive state. This prevents sodium influx, halting the generation and propagation of action potentials, which temporarily stops pain signal transmission.

The dosage of mepivacaine is determined by the prescribing clinician based on the specific procedure, patient characteristics, and route of administration. Dosing guidelines are provided in the product labeling and must be followed by the healthcare professional.

Safety data for mepivacaine in pregnancy are limited, and it is classified as a Category C/unknown agent. It should only be used when the potential benefit justifies the potential risk to the fetus. Limited information is available for breastfeeding; caution is advised.

Enquiries are submitted via the product page on gnhindia.com, where you specify the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mepivacaine has a rapid onset and intermediate duration, similar to lidocaine but with slightly longer analgesia. Compared with bupivacaine, it has a shorter duration and lower cardiotoxic potential, making it useful when a moderate length of anesthesia is desired.

Store the product at controlled room temperature, typically below 25 °C. Keep the vial in its original packaging, protect it from light and moisture, and ensure the container is tightly sealed to maintain sterility.

Mepivacaine is administered by injection. It can be given epidurally, intramuscularly, or perineurally, depending on the clinical indication. The injection technique follows standard aseptic procedures and the specific dosing recommendations of the prescribing clinician.

Serious risks include allergic reactions such as anaphylaxis, cardiac arrhythmias, and central nervous system toxicity leading to seizures. Immediate medical attention is required if any of these events occur during or after administration.

Patients with a known hypersensitivity to amide‑type local anesthetics, those with severe hepatic impairment, or individuals with certain cardiac conduction disorders should avoid mepivacaine unless a risk‑benefit assessment justifies its use.